Table 2.
Absolute and relative frequencies of adverse reactions after the first and the second dose and completed vaccination schedule of BNT162b2.
| Signs/Symptoms | First Dose (n = 293) N, % |
Second Dose (n = 293) N, % |
p * | Grade of Daily Activities Limitation after the First Dose Median, IQR |
Grade of Daily Activities Limitation after the Second Dose Median, IQR |
p ** |
|---|---|---|---|---|---|---|
| At least 1 localized/systemic | 149 (50.9) | 235 (80.2) | <0.001 | - | - | - |
| At least 1 localized | 142 (48.5) | 219 (74.7) | <0.001 | - | - | - |
| Pain | 137 (46.8) | 217 (74.1) | <0.001 | 2 (1–3) | 3 (2–4) | <0.001 |
| Redness | 9 (3.1) | 19 (6.5) | 0.0184 | 1 (1–3) | 2 (1–3) | 0.6698 |
| Swelling | 37 (12.6) | 57 (19.5) | <0.001 | 2 (1–3) | 3 (1–3) | 0.0406 |
| Other local reactions | 17 (5.8) | 19 (6.9) | 0.7150 | 3 (3–3) | 2 (2–4) | 0.7815 |
| At least 1 systemic | 64 (21.8) | 206 (70.3) | <0.001 | - | - | - |
| Fever (>37.5 °C) | 5 (1.7) | 85 (29.0) | <0.001 | 4 (3–5) | 4 (3–4) | 0.3173 |
| Shivers | 21 (7.2) | 131 (44.7) | <0.001 | 3 (2–4) | 3 (2–4) | 0.1172 |
| Joint pain | 25 (8.5) | 137 (46.8) | <0.001 | 2 (2–4) | 3 (2–4) | 0.0034 |
| Muscular pain | 30 (10.2) | 139 (47.4) | <0.001 | 2 (2–3) | 3 (2–4) | 0.0154 |
| Headache | 39 (13.3) | 136 (46.4) | <0.001 | 3 (2–4) | 3 (2–4) | 0.3340 |
| Asthenia | 39 (13.3) | 148 (50.5) | <0.001 | 3 (2–4) | 3 (2–4) | 0.0975 |
| Lymphonodal swelling | 7 (2.4) | 31 (10.6) | <0.001 | 2 (1–3) | 2 (2–3) | 0.1025 |
| Nausea | 18 (6.1) | 61 (20.8) | <0.001 | 2 (2–4) | 3 (2–4) | 0.0842 |
| Other systemic reactions | 18 (6.1) | 46 (15.7) | <0.001 | 3 (2–4) | 3 (2–4) | 0.8689 |
* McNemar test, ** Wilcoxon test.